AstraZeneca And Guangzhou Medical College Conduct Pulmonary Disease Study
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca Research Foundation and No. 1 Affiliated Hospital of Guangzhou Medical College have signed an agreement to jointly conduct basic research on chronic obstructive pulmonary disease. This represents the first MNC study on COPD in China. The hospital's national key laboratory of respiratory disease will undertake a two-year study into the reason for the disease's progress by observing 500 patients with COPD and comparing them with healthy controls. In China, COPD has an incidence of 8.4 percent but more than half the patients are not aware of the disease. Experts hope to instil the concept among healthcare workers that COPD is preventable and treatable. (Click here for more - Chinese language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.